Investing.com - Goodrx (NASDAQ: GDRX) reported third quarter EPS of $0.06, in line with the analyst estimate of $0.06. Revenue for the quarter came in at $180M versus the consensus estimate of $188.52M.
Guidance
Goodrx sees Q4 2023 revenue of $188.00M-$194.00M versus the analyst consensus of $192.70M.
Goodrx sees FY 2023 revenue of $742.00M-$748.00M versus the analyst consensus of $754.90M.
Goodrx's stock price closed at $5.47. It is down -30.85% in the last 3 months and up 9.62% in the last 12 months.
Goodrx saw 2 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Goodrx's stock price’s past reactions to earnings here.
According to InvestingPro, Goodrx's Financial Health score is "great performance".
Check out Goodrx's recent earnings performance, and Goodrx's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar